CD8A and neoplasm: The data suggested that atezolizumab alone can only induce the activation of the immune response in tumor infiltrating lymphocytes (TILs) in MSI tumors, while the combination therapy of atezolizumab plus tiragolumab was able to reactive CD8+ TILs in 46% of MSS CRC patients.